Abstract
Conditioned medium from the human tumor cell line HBT 5637 possesses a unique hematopoietic activity, originally termed hemopoietin-1. Hemopoietin-1 alone does not stimulate bone marrow colony formation or proliferative responsesin vitro, but rather potentiates responses to other hematopoietic growth factors, such as CSF-1 and GM-CSF. In studies designed to characterize the molecular nature of this factor, it was found by molecular, biochemical biological and serological criteria that all the hemopoietin-1 like activity could be attributed to IL-1α. The therapeutic potential of IL-1 was then tested in a system where myelopoiesis is depressed by whole body irradiation. After 750 R irradiation, mice were administered IL-1 twice daily for the duration of the experiment. Mice which received IL-1 treatment had an accelerated recovery of marrow colony forming capacity which was also reflected by significantly higher blood neutrophil levels as compared to control irradiated mice. IL-1 treated irradiated mice also had a significant increase in resistance to bacterial challenge 14 days post irradiation. Thus, IL-1 treatment was effective in augmenting myelopoiesis following sublethal whole body irradiation. The effects of the IL-1 treatment on the recovery of lymphocyte numbers was also assessed. Here the IL-1 treated irradiated mice had fewer lymphocytes and depressed mitogen responses by spleen cells. Indeed the thymus of the IL-1 treated irradiated mice remained chronically hypoplastic for the duration of the experiment. Although IL-1 treatment increased myeloid progenitors in the bone marrow, it caused a decrease in the frequency of pre-B cells. Thus, IL-1 administration is an effective treatment for accelerating myeloid recovery following the cytore ductive effects of irradiation, but the myelopoietic augmentation may be at the expense of lymphoid recovery.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Metcalf D. The granulocyte-macrophage colony stimulating factors. Cell 1985; 43: 5–6.
Bartelmez SH, Stanley ER. Synergism between hemopoietic growth factors (HGFs) detected by their effects on cells bearing receptors for a lineage specific HGF: Assay for hemopoietin-1. J Cell Physiol 1985; 122: 370–8.
Jubinsky PT, Stanley ER. Purification of hemopoietin 1: A multilineage hemopoietic growth factor. Proc Natl Acad Sci USA 1985; 82: 2764–8.
Kreigler AB, Bradley TR, Januszewicz E, Hodgson GS and Elms ET. Partial purification and characterization of a growth factor for macrophage progenitor cells with high proliferative potential in mouse bone marrow. Blood 1982; 60: 503–8.
Bradley TR, and Hodgson GS. Detection of primitive macrophage progenitor cells in mouse marrow. Blood 1979; 54: 1446 - 50.
Mochizuki DY, Eisenman JR, Conlon PJ, Larsen AD, Tushinski RJ. Interleukin 1 regulates hematopoietic activity, a role previously ascribed to hemopoietin 1. Proc Natl Acad Sci USA 1987; 84: 5267–71.
Morrissey PJ, Charrier K, Bressler L, Alpert A. The influence of IL-1 treatment on the reconstitution of the hemopoietic and immune systems after sublethal radiation. J Immunol 1988; 140: 4204–10.
Watson JD, Crosier PS, March CJ, Conlon PJ, Mochizuki DY, Gillis S, Urdal DL. Purification to homogeneity of a human hematopoietic growth factor that stimulates the growth of a murine interleukin 3-dependent cell line. J Immunol 1986; 137: 854–7.
Conlon PJ. A rapid biological assay for the detection of IL-1. J Immunol 1983; 131: 1280–6.
Creaven PJ, Mihich E. The clinical toxicity of anti-cancer drugs and its prediction. Semin Oncol 1977; 4: 147–63.
Hoaglund HE. Hematological complications of cancer chemotherapy. Semin Oncol 1982; 9: 95–106.
Winston DJ, Ho WG, Champlin RE, Gale RP. Infectious complications of bone marrow transplantation. Exp Hematol 1984; 12: 205–26.
Sauto K, Nakano M, Akiyama T, Ushiba D. Passive transfer of immunity to typhoid by macrophages. J Bacteriol 1962; 84: 800–11.
Anderson RE, Warner NL. Ionizing radiation and the immune response. Adv Immunol 1975; 24: 215–335.
Durum SK, Schmidt JA, Oppenheim JJ. Interleukin 1; An immunological perspective. Ann Rev Immunol 1985; 3: 263–87.
Kincade PW, Lee G, Watanabe T, Sun L, Scheid MP. Antigens displayed on murine B lymphocyte precursors. J Immunol 1981; 127: 2262–8.
Springer T, Galfre' G, Secher DS, Milstein C. Mac-1; a macrophage differentiation antigen identified by monoclonal antibody. Eur J Immunol 1979; 9: 301–6.
Spivak JL, Smith RRL, Ihle JN. Interleukin 3 promotes thein vitro proliferation of murine pluripotent hematopoietic stem cells. J Clin Invest 1985; 76: 1613–20.
Peschel C, Paul WE, Ohara J, Green I. Effects of B cell stimulatory factor/interleukin 4 on hematopoietic progenitor cells. Blood 1970; 70: 254–63.
Ikebuchi K, Wong GG, Clark S, Ihle IN, Hirai Y, Ogawa M. Interleukin 6 enhancement of interleukin 3-dependent proliferation of hematopoietic progenitors. Proc Natl Acad Sci USA 1987; 84: 9035–9.
Vogel SN, Douches SD, Kaufman EN, Neta R. Induction of colony stimulating factorin vivo by recombinant IL-1α and recombinant tumor necrosis factor. J Immunol 1987; 138: 2143–8.
Zucali JR, Dinarello CA, Oblon J, Gross MA, Anderson L, Weiner RS. Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony stimulating activity and prostaglandin E2. J Clin Invest 1986; 77: 1857–63.
Takacs L, Kovacs EJ, Smith MR, Young HA, Durum SK. Detection of IL-1α and IL-1β gene expression byin situ hybridization: Tissue localization of IL-1 mRNA in the normal C57BL/6 mouse. J Immunol 1988; 141: 3081–95.
Morrissey PJ, Charrier K, Alpert A, Bressler L.In vivo administration of IL-1 induces thymic hypoplasia and increased levels of serum corticosterone. J Immunol 1988; 141: 1456–63.
Reichert RA, Weisman IL, Butcher ER. Dual immunofluorescence studies of cortisone-induced thymus involution: evidence for a major cortical component to cortisone resistant thymocytes. J Immunol 1986; 136: 3529–36.
Dorshkind K. IL-1 inhibits B cell differentiation in long term bone marrow cultures. J Immunol 1988; 141: 531–8.
Van der Meer JWM, Barza M, Wolff SM, Dinarello CA. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci USA 1988; 1620-3.
Gladue R, Einard A, Newborg M. Enhanced antibacterial resistance in neutropenic mice treated with human recombinant interleukin-1 beta. Agents and Actions 1988; 24: 130–6.
McIntyre KW, Unowsky J, De Lorenzo W, Benjamin W. Enhancement of antibacterial resistance of neutropenic bone marrow-suppressed mice by interleukin 1α. Infect Immun 1989; 57: 48–54.
Ozaki Y, Ohashi T, Minami A, Nakamura S. Enhanced resistance of mice to bacterial infection induced by human interleukin 1α. Infect Immun 1987; 55: 1436–46.
Czupryski CJ, Brown JF, Young KM, Cooley AJ, Kurtz RS. Effects of murine recombinant IL-1 on the host response to infection. J Immunol 1988; 140: 962–8.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morrissey, P.J., Mochizuki, D.Y. Interleukin-1 is identical to hemopoietin-1: Studies on its therapeutic effects on myelopoiesis and lymphopoiesis. Biotherapy 1, 281–291 (1989). https://doi.org/10.1007/BF02171004
Issue Date:
DOI: https://doi.org/10.1007/BF02171004